Phibro Animal Health Corporation

PAHC Healthcare Drug Manufacturers Specialty & Generic

Phibro Animal Health Corporation’s revenue for fiscal 2026 (year ended June 2026) was $1.5 billion, up 17.1% from fiscal 2025. In the quarter to June 2026, revenue grew 4.77%, EPS grew 28.6%, free cash flow fell 35.7% and total debt rose 1.96%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

38.82 0.84 +2.21%
Market cap
$1.5B
P/E
15.8×
Fwd P/E
11.1×
Dividend yield
1.24%
F-score
6/9
Altman Z
2.95
Beneish M
−2.39
Dividend safety
47/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

23.79% 31.80% 30.34% 29.72%
Piotroski F-Score
5 7 7 6
ROA
5.77% 6.84% 6.90% 6.97%
ROIC
9.29% 10.67% 11.03% 11.72%
Return on Tangible Assets
7.37% 9.85% 9.80% 10.09%
Average Days of Receivables
56.82 53.81 53.91 57.41
Free Cash Flow per Share
0.85 1.17 0.31 0.24
Free Cash Flow
34.29 47.29 12.77 9.87
Other line items

Show all line items

Columns are period end dates